Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
Eisai Inc. and Merck (NYSE:...
Read MoreBioMarin Pharmaceutical Inc. (BMRN) said...
Read MoreAbbott Laboratories’ Amplatzer Amulet left...
Read MorePfizer Inc. (NYSE:PFE) announced today...
Read MoreAmgen (NASDAQ:AMGN) today announced a...
Read MorePerkinElmer, Inc., a global leader...
Read MoreMedlife, a healthcare company and...
Read MorePfizer Inc. ( PFE )...
Read MoreStayHappi is a self-funded start-up...
Read More